In a recent development in the pharmaceutical industry, Celltrion Healthcare has appealed to a London court seeking to invalidate a patent owned by Novartis and Genentech. The patent in question pertains to a drug used commonly for the management of severe asthma and chronic hives. Celltrion Healthcare has initiated this legal action as part of its strategy to introduce a biosimilar product into the market.
Novartis, the Swiss pharma behemoth, and Genentech based in California are both formidable players in the global pharmaceutical market. This particular drug, protected under their shared patent, has evidently caught the attention of Celltrion Healthcare.
The South Korean pharmaceutical company appears to be gearing up for the launch of a biosimilar – a biological product that is nearly identical to the original product but developed independently. The ongoing court proceedings indicate that Celltrion is committed to removing legal barriers that could potentially impede the successful launch of its biosimilar product.
While the consequences of this lawsuit could have industry-changing implications, one can only speculate as of now. The outcome will indeed be followed closely by legal and healthcare professionals globally. You can find more detailed insights on this development at Law360.